Publications

Locatelli F, Whitlock JA, Peters C, Chen-Santel C, Chia V, Dennis RM, … Kelsh MA, et al. 2020. Blinatumomab versus historical standard therapy in pediatric patients with relapsed/refractory Ph-negative B-cell precursor acute lymphoblastic leukemia. Leukemia 34(9):2473–2478; doi: 10.1038/s41375-020-0770-8. PMID: 32094465.

Elbeddini A, Hooda N, Yang L. 2020. Role of Canadian pharmacists in managing drug shortage concerns amid the COVID-19 pandemic. Canad Pharmacists J 153(4)198-203; doi: 10.1177/1715163520929387.

Fergie J, Suh M, Jiang X, Fryzek JP, Gonzales T. 2020. Respiratory syncytial virus and all-cause bronchiolitis hospitalizations among preterm infants using the Pediatric Health Information System (PHIS). J Infect Dis 225(7):1197-1204; doi: 10.1093/infdis/jiaa435.

Sacks NC, Healey B, Cyr PL, Batt K, Henig NR. The economic burden of bronchiolitis obliterans syndrome (BOS) in allogenic hematopoietic stem cell transplant (alloHSCT) patients with Medicare coverage. Poster presentation, ISPOR 25th Annual International Meeting, Orlando, FL, May 2020.

Dean R, Arjunji R, Awano H, Igarash A^, Tanaka A, Jensen IS, Cyr PL et al. Cost-effectiveness of onasemnogene abeparvocec (ZOLGENSMA) for spinal muscular atrophy type 1 against nusinersen in Japan. ISPOR 25th Annual International Meeting, Orlando FL, 2020.

Sacks NC, Healey B, Cyr PL, Graham R. Economic burden of X-linked myotubular myopathy (XLMTM) by ventilation status. ISPOR 25th Annual International Meeting, Orlando FL, 2020.

Miller B, Jensen IS, Dean R, Cyr PL, Slocomb T, James E, Beggs AH. Health resource use in patients with x-linked myotubular myopathy (XLMTM): Data from the RECENSUS Study. ISPOR 25th Annual International Meeting, Orlando FL, 2020.

Miller B, Yao W, Dean R, Jensen I, Cyr PL, Slocomb T. Understanding the impact of XLMTM on parents and caregivers in the US: An analysis of survey results. ISPOR 18^th Annual European Meeting, Milan Italy, 2020.

Jensen IS, Hathway J, Cyr PL, Gauden D, Gardiner P. 2020. Cost–consequence analysis of ¹⁸F-fluciclovine for the staging of recurrent prostate cancer. J Mark Access Health Pol 8(1):1749362; doi: 10.1080/20016689.2020.1749362.

Hathway J, Miller-Wilson L, Jensen I, Ozbay B, Regan C, Jena A, et al. 2020. Projecting total costs and health consequences of increasing mt-sDNA utilization for colorectal cancer screening from the payer and integrated delivery network perspectives. J Med Econ 23(6):581-592; doi: 10.1080/13696998.2020.1730123.